Avadel Pharmaceuticals plc – NASDAQ:AVDL
Avadel Pharmaceuticals stock price today
$13.75
+3.21
+30.46%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Avadel Pharmaceuticals stock price monthly change
-36.51%
month
Avadel Pharmaceuticals stock price quarterly change
-36.51%
quarter
Avadel Pharmaceuticals stock price yearly change
-26.81%
year
Avadel Pharmaceuticals key metrics
Market Cap | 966.98M |
Enterprise value | 627.93M |
P/E | -4.11 |
EV/Sales | N/A |
EV/EBITDA | -4.02 |
Price/Sales | N/A |
Price/Book | -26.99 |
PEG ratio | 0.05 |
EPS | -1.83 |
Revenue | 55.14M |
EBITDA | -133.86M |
Income | -156.83M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -242.77% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAvadel Pharmaceuticals stock price history
Avadel Pharmaceuticals stock forecast
Avadel Pharmaceuticals financial statements
Average Price Target
$30
Potential upside: 118.18%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.49M | -64.43M | -4306.95% |
|---|---|---|---|
| Sep 2023 | 7.01M | -36.27M | -517.17% |
| Dec 2023 | 19.45M | -28.78M | -147.98% |
| Mar 2024 | 27.17M | -27.34M | -100.6% |
| 2023-11-08 | -0.35 | -0.41 |
|---|---|---|
| 2024-03-04 | -0.28 | -0.32 |
| Jun 2023 | 200976000 | 57.78M | 28.75% |
|---|---|---|---|
| Sep 2023 | 203100000 | 92.95M | 45.77% |
| Dec 2023 | 261125999 | 173.38M | 66.4% |
| Mar 2024 | 167899000 | 89.51M | 53.31% |
| Jun 2023 | -32.02M | -92.90M | 91.54M |
|---|---|---|---|
| Sep 2023 | -38.22M | 9.82M | 30.46M |
| Dec 2023 | -28.02M | 27.92M | -21.11M |
| Mar 2024 | -29.70M | 21.38M | 13.19M |
Avadel Pharmaceuticals alternative data
| Aug 2023 | 41 |
|---|---|
| Sep 2023 | 41 |
| Oct 2023 | 41 |
| Nov 2023 | 41 |
| Dec 2023 | 41 |
| Jan 2024 | 41 |
| Feb 2024 | 41 |
| Mar 2024 | 154 |
| Apr 2024 | 154 |
| May 2024 | 154 |
| Jun 2024 | 154 |
| Jul 2024 | 154 |
Avadel Pharmaceuticals other data
44.41%
-40.22%
of AVDL is owned by hedge funds
56
-27
26.68M
-24.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 2000 | 0 |
| Dec 2024 | 38279 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MCHUGH THOMAS S officer: Chief Financial Officer | Ordinary Shares | 5,000 | $10.49 | $52,435 | ||
Purchase | GLASS GEOFFREY MICHAEL director | Ordinary Shares | 10,204 | $9.8 | $99,999 | ||
Purchase | GLASS GEOFFREY MICHAEL director | Ordinary Shares | 10,075 | $9.89 | $99,642 | ||
Purchase | DIVIS GREGORY J director, officer.. | Ordinary Shares | 402 | $9.82 | $3,948 | ||
Purchase | PALCZUK LINDA director | Ordinary Shares | 3,000 | $10.19 | $30,567 | ||
Purchase | DIVIS GREGORY J director, officer.. | Ordinary Shares | 9,598 | $9.98 | $95,759 | ||
Purchase | MCHUGH THOMAS S officer: Chief Financial Officer | ADSs | 2,000 | $14.5 | $29,000 | ||
Sale | MCCAMISH MARK ANTHONY director | ADSs | 75,000 | $14.53 | $1,089,750 | ||
Purchase | MCHUGH THOMAS S officer: Chief Financial Officer | ADSs | 2,000 | $14.45 | $28,900 | ||
Purchase | DIVIS GREGORY J director, officer.. | ADSs | 10,000 | $13.2 | $132,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 4 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Jazz Pharmaceuticals: One Step Forward, One Back
3 Oversold Biotech Names
Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Updated View On Jazz Pharmaceuticals' 2025 Goals
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Avadel May Continue To Outperform With Positive Launch Momentum
-
What's the price of Avadel Pharmaceuticals stock today?
One share of Avadel Pharmaceuticals stock can currently be purchased for approximately $13.75.
-
When is Avadel Pharmaceuticals's next earnings date?
Unfortunately, Avadel Pharmaceuticals's (AVDL) next earnings date is currently unknown.
-
Does Avadel Pharmaceuticals pay dividends?
No, Avadel Pharmaceuticals does not pay dividends.
-
How much money does Avadel Pharmaceuticals make?
Avadel Pharmaceuticals has a market capitalization of 966.98M. Avadel Pharmaceuticals made a loss 160.28M US dollars in net income (profit) last year or -$0.32 on an earnings per share basis.
-
What is Avadel Pharmaceuticals's stock symbol?
Avadel Pharmaceuticals plc is traded on the NASDAQ under the ticker symbol "AVDL".
-
What is Avadel Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Avadel Pharmaceuticals?
Shares of Avadel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Avadel Pharmaceuticals's key executives?
Avadel Pharmaceuticals's management team includes the following people:
- Mr. Gregory J. Divis Jr. Chief Executive Officer & Director(age: 58, pay: $897,000)
- Dr. Jordan S. Dubow M.D. Consultant(age: 47, pay: $727,930)
- Mr. Thomas S. McHugh Senior Vice President & Chief Financial Officer(age: 60, pay: $581,200)
-
How many employees does Avadel Pharmaceuticals have?
As Jul 2024, Avadel Pharmaceuticals employs 154 workers.
-
When Avadel Pharmaceuticals went public?
Avadel Pharmaceuticals plc is publicly traded company for more then 29 years since IPO on 7 Jun 1996.
-
What is Avadel Pharmaceuticals's official website?
The official website for Avadel Pharmaceuticals is avadel.com.
-
How can i contact Avadel Pharmaceuticals?
Avadel Pharmaceuticals can be reached via phone at +353 1 901 5201.
-
What is Avadel Pharmaceuticals stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Avadel Pharmaceuticals in the last 12 months, the avarage price target is $30. The average price target represents a 118.18% change from the last price of $13.75.
Avadel Pharmaceuticals company profile:
Avadel Pharmaceuticals plc
avadel.comExchange:
NASDAQ
Full time employees:
154
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
10 Earlsfort Terrace
Dublin, 2
Dublin, 2
CIK: 0001012477
ISIN: US05337M1045
CUSIP: 05337M104
